Estimated read time: 4-5 minutes
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
[STK]
[IN] HEA PHA MTC
[SU]
-- WITH PHOTO -- TO HEALTH, AND MEDICAL EDITORS:
Valensa Announces Availability of ZanthinNEX@ Astaxanthin in Q4 2014
ORLANDO, Fla., March 17, 2014 /PRNewswire/ -- Valensa International
announced today that it will begin to offer ZanthinNEX@ Astaxanthin
commercially in late 2014. ZanthinNEX is a form of the carotenoid
Astaxanthin produced via a proprietary process using natural enzymatic
conversions that delivers a safe finished product that is 'nature
equivalent' to conventional Astaxanthin produced via extraction from
Haematococcus pluvialis. In this instance, the nature equivalence of
ZanthinNEX means that it has the same exact composition and isomeric
structure (e.g. S, S' Astaxanthin) as the Astaxanthin found in natural
algae and wild salmon - and will function in the human body exactly as
an algae-derived product would. Safety and bioequivalence testing for
ZanthinNEX have been conducted. Valensa expects to complete regulatory
approvals and anticipates no issues for GRAS approvals prior to
commercial launch. This new source will help meet market demand for
Astaxanthin, which is currently exceeding industry supply. The
availability of ZanthinNEX will not be impacted by seasonal variances
of quality and quantity such as is encountered with algae-derived
Astaxanthin.
Photo - http://photos.prnewswire.com/prnh/20140317/PH84422
According to Dr. Rudi E. Moerck, CEO & President, Valensa's
commitments to better health through natural products and to the
science of Astaxanthin were the driving forces behind the development
of this nature equivalent ingredient. "Valensa has more than a decade
of experience with Astaxanthin for the support human health. We led
the use of supercritical CO2 as a nature-friendly extraction
technology for Astaxanthin. We were the first to achieve Novel Foods
approvals in Europe with our Zanthin@ brand, which requires a
commitment to purity and safety. We have been at the forefront of safe
and economical dosage recommendations for this ingredient - where
we've actually suggested that lower doses are sufficient and highly
effective. And we have developed a novel, natural stabilization system
that significantly extends the storage stability of Astaxanthin. In
all of these areas, our goal remains to offer the most natural, stable
and efficacious Astaxanthin ingredient to the market. ZanthinNEX is
the result of our commitment to a scientifically superior, safe, and
truly nature equivalent Astaxanthin offering," he said. "When we talk
about a 'nature equivalent' ingredient, it means we employ natural
enzyme-based conversion to create the critical raw material necessary
to manufacture ZanthinNEX. By analogy, in traditional Astaxanthin
manufacture, Haematococcus pluvialis microalgae starts with in situ
synthesized beta carotene as the initial building block, which is then
converted in many complex enzymatic steps to yield S, S'-Astaxanthin.
We use a related process to make ZanthinNEX by employing advanced
enzyme-based technology to create the final correct optical centers in
ZanthinNEX, totally matching the Astaxanthin made with algae, but
without some of the unwanted byproducts found in algae-derived
Astaxanthin. The final product is actually of higher assay and purity
than Astaxanthin produced in open ponds or even closed photo
bioreactor systems, without the taste and odor issues encountered in
some natural Astaxanthin extracts," he said.
New technology, equivalent product form and great formulation
potential
Testing has shown that ZanthinNEX is significantly more bioavailable
than Astaxanthin made from algae because of several factors, including
much higher purity levels. This enhanced bioavailability could lead to
lower supplementation levels in finished products, with potentially
lower costs for consumers. Like Valensa's flagship Astaxanthin product
- Zanthin Natural Astaxanthin - ZanthinNEX will be stabilized using
the proprietary O2B@ Peroxidation Blocker stabilization system to
provide long-term product stability and higher efficacy for the
consumer. Valensa will continue to expand its Zanthin Natural
Astaxanthin Complex business alongside ZanthinNEX. Zanthin Natural
Astaxanthin has become a key ingredient in a wide range of
condition-specific products that Valensa sells, and which have become
highly successful in the marketplace.
According to Moerck, the natural products industry is frustrated by
the inability of suppliers to ramp up production to meet demand that
has grown from high profile endorsements by industry thought leaders
and fast-selling products based on the ingredient. "One of the
drawbacks in being in this wonderful industry we call 'natural
products' is that we rely on nature for our raw materials. Nature
doesn't always cooperate with us the way we'd like, and when you get a
difficult-to-manufacture ingredient like Astaxanthin becoming hot at
the consumer level, the temptation is to cut corners," he said. "We
need to resist that temptation and hold the line against substituting
synthetic products. For this reason, the products that we offer our
customers should be based on optically active materials just like in
nature. They should be studied for safety, efficacy, and
bioequivalence and supported by sound science. To do anything less
than this goes against our customer's expectations.
For further information contact: Dr. Rudi Moerck, President & CEO
Voice: 210-632-0695 Fax: 352-483-2095 www.valensa.com
Read more news from Valensa International.
SOURCE Valensa International
-0- 03/17/2014
/Photo: http://photos.prnewswire.com/prnh/20140317/PH84422
PRN Photo Desk, photodesk@prnewswire.com
/Web Site: http://www.valensa.com
CO: Valensa International
ST: Florida
IN: HEA PHA MTC
PRN
-- PH84422 --
0000 03/17/2014 13:59:00 EDT http://www.prnewswire.com
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
